Expression of p21WAF1/CIP1 and p53 proteins in gastric carcinoma:: its relationships with cell proliferation activity and prognosis

被引:36
作者
Liu, XP
Tsushimi, K
Tsushimi, M
Kawauchi, S
Oga, A
Furuya, T
Sasaki, K
机构
[1] Yamaguchi Univ, Sch Med, Dept Pathol, Ube, Yamaguchi 7558505, Japan
[2] Tsushimi Hosp, Dept Surg, Yamaguchi 7580041, Japan
关键词
gastric carcinoma; immunohistochemistry; p21(WAF1/CIP1); p53; Ki-67; antigen; prognosis;
D O I
10.1016/S0304-3835(01)00589-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The expressions of p21(WAF1/CIP1), p53 proteins, and Ki-67 antigen were investigated immunohistochemic ally in 190 primary gastric carcinomas. Of the 190 tumors, 40.5% positively expressed p21(WAF1/CIP1) and 42.1% positively expressed p53. The expression of p21(WAF1/CIP1) was significantly associated with clinicopathological factors including gender, tumor size, status of lymph node, and clinicopathological stage (P < 0.05 for all), but p21(WAF1/CIP1) expression showed no clear correlation with Ki-67 labeling index. The mean Ki-67 labeling index was significantly higher in p53-positive cases than p53-negative, cases (P < 0.0001). However, among the clinicopathological factors examined, expression of p53 correlated only with age. Univariate and multivariate survival analyses revealed that clinicopathological stage (P < 0.001) and expression status of p21(WAF1/CIP1) (P < 0.05) were independent prognostic factors. Neither the expression status of p53 nor the Ki-67 labeling index, however, influenced the prognosis of patients with gastric cancer. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:183 / 189
页数:7
相关论文
共 37 条
  • [1] FREQUENT AMPLIFICATION OF THE CYCLIN-E GENE IN HUMAN GASTRIC CARCINOMAS
    AKAMA, Y
    YASUI, W
    YOKOZAKI, H
    KUNIYASU, H
    KITAHARA, K
    ISHIKAWA, T
    TAHARA, E
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (07): : 617 - 621
  • [2] EXPRESSION OF P21(WAF1/CIP1) IS HETEROGENEOUS AND UNRELATED TO PROLIFERATION INDEX IN HUMAN OVARIAN-CARCINOMA
    BARBOULE, N
    MAZARS, P
    BALDIN, V
    VIDAL, S
    JOZAN, S
    MARTEL, P
    VALETTE, A
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (05) : 611 - 615
  • [3] Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO
  • [4] 2-6
  • [5] WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION
    ELDEIRY, WS
    TOKINO, T
    VELCULESCU, VE
    LEVY, DB
    PARSONS, R
    TRENT, JM
    LIN, D
    MERCER, WE
    KINZLER, KW
    VOGELSTEIN, B
    [J]. CELL, 1993, 75 (04) : 817 - 825
  • [6] GABBERT HE, 1995, CANCER, V76, P720, DOI 10.1002/1097-0142(19950901)76:5<720::AID-CNCR2820760503>3.0.CO
  • [7] 2-E
  • [8] *GASTR CANC ASS, 1998, GASTRIC CANC, V1, P10
  • [9] GERDES J, 1984, J IMMUNOL, V133, P1710
  • [10] Gomyo Y, 1997, CANCER, V79, P2067, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2067::AID-CNCR3>3.0.CO